San Diego-based Arcturus Therapeutics and Canadian company Precision NanoSystems announced a partnership for the manufacture of RNA medicines.

Under the terms of the agreement, Precision’s proprietary platform, NanoAssemblr, will be used to support clinical studies and commercial development for RNA medicines developed using Arcturus’ proprietary RNA therapeutics platform, LUNAR.

“We are delighted to partner with Arcturus to advance their pipeline of RNA medicines for the treatment of rare diseases,” said James Taylor, CEO of Precision. “We have been working very closely with Arcturus during the discovery phase of the LUNAR products and we are excited to support ongoing development through clinical manufacture using our NanoAssemblr microfluidics-based platform for the manufacture of nanomedicines.”

In November, Arcturus announced its expansion to new office headquarters and laboratory space in the Torrey Ridge Science Center from the Johnson & Johnson Innovation Center.